Haleon
HLN (FTSE)
Haleon, a UK consumer health company known for its pain relief, digestive health, and oral care products, is a noteworthy investment on the FTSE 250 under the ticker HLN. With a dividend yield of nearly 2%, it provides a reliable income stream despite a challenging 1-year return of -10.98%. Analysts maintain a strong outlook, setting a median 12-month price target of $10.20, reflecting confidence in its growth potential.
Pros:
- Diverse consumer health product range
- Established brand recognition
- Potential for revenue growth
Cons:
- Recent stock price decline
- Market competition
- Dependence on consumer trends
Haleon (HLN) may be a suitable investment for those seeking exposure to the consumer health sector, particularly investors looking for a dividend yield of 1.96% and a long-term growth potential, as indicated by its 5-year return of 23.20%. However, potential investors should consider the recent challenges reflected in the 1-year return of -10.98% and assess their risk tolerance accordingly.